Hefiya

Adalimumab, the active ingredient in Hefiya, is a tumor necrosis factor (TNF) inhibitor presented as a subcutaneous injection for subcutaneous use. It is prescribed to reduce inflammation in autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

GNH USA supplies Hefiya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products globally.

Adalimumab acts on the TNF‑α pathway to control inflammation in several autoimmune diseases.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: alleviates skin and joint symptoms and improves function. - Ankylosing spondylitis: decreases spinal inflammation and improves mobility. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Plaque psoriasis: clears skin lesions and reduces scaling.

Adalimumab may cause a range of adverse reactions, from mild injection‑site irritation to serious systemic events.

Common Side Effects: - Injection site pain or redness. - Upper respiratory tract infection. - Headache. - Nausea. - Rash.

Serious or Rare Side Effects: - Serious infections such as tuberculosis or fungal sepsis. - Malignancies including lymphoma. - Demyelinating disorders of the central nervous system. - New‑onset or worsening heart failure. - Lupus‑like syndrome. - Hepatic injury or elevated liver enzymes.

Before starting therapy, patients and clinicians should consider several safety measures.

- Screen for active infections: evaluate and treat any infection prior to initiation. - Assess tuberculosis risk: perform TB testing and consider prophylaxis if indicated. - Monitor for malignancy: conduct regular skin examinations and cancer screenings. - Evaluate cardiac status: avoid use in patients with moderate to severe heart failure. - Vaccination guidance: avoid live vaccines during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - Concurrent biologic therapies: increase risk of serious infections. - Severe uncontrolled infection: therapy should be withheld.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., methotrexate, azathioprine): may enhance immunosuppression. - Antifungal agents (e.g., azoles): monitor for additive infection risk. - Tuberculosis prophylaxis drugs: adjust monitoring for liver toxicity.